Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Bayer AG (ETR: BAYN) announced that China's National Medical Products Administration (NMPA) has approved Sunharbo (asundexian tablets), the world's first (first‑in‑class) activated Factor XI (FXIa) inhibitor, for reducing the risk…

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-7782 Clinical Trials in Advanced Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-7782 Clinical Trials in Advanced Solid Tumors

SineuGene's First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance
CompanyDrug

SineuGene’s First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance

Qihan Biotech's QT-019B Gains FDA IND Approval for Autoimmune Diseases
CompanyDrug

Qihan Biotech’s QT-019B Gains FDA IND Approval for Autoimmune Diseases

Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials
CompanyDrug

Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials

Jiangsu Hengrui's Combo Therapy Approved for Clinical Trials by NMPA
CompanyDrug

Jiangsu Hengrui’s Combo Therapy Approved for Clinical Trials by NMPA

Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer
CompanyDrug

Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
CompanyDrug

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors
CompanyDrug

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors

Show More